Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Personalized medicine — a new reality in psoriatic arthritis?

Some patients with psoriatic arthritis are refractive to one biologic therapy but not to others, and a strategy for selecting the right therapy for each patient is needed. The findings of a new study highlight the potential benefit of stratifying patients by their immunophenotype to select the optimal biologic to use.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Immunophenotyping strategy for precision medicine.


  1. Nograles, K. E., Brasington, R. D. & Bowcock, A. M. New insights into the pathogenesis and genetics of psoriatic arthritis. Nat. Clin. Pract. Rheumatol. 5, 83–91 (2009).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Miyagawa, I. et al. Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. Rheumatology (Oxford) (2018).

    Article  Google Scholar 

  3. Diani, M., Altomare, G. & Reali, E. T cell responses in psoriasis and psoriatic arthritis. Autoimmun. Rev. 14, 286–292 (2015).

    Article  PubMed  CAS  Google Scholar 

  4. Crome, S. Q., Wang, A. Y. & Levings, M. K. Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease. Clin. Exp. Immunol. 159, 109–119 (2010).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Kestens, L. et al. Selective increase of activation antigens HLA-DR and CD38 on CD4+ CD45RO+ T lymphocytes during HIV-1 infection. Clin. Exp. Immunol. 95, 436–441 (1994).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Langley, R. G. et al. Secukinumab in plaque psoriasis — results of two phase 3 trials. N. Engl. J. Med. 371, 326–338 (2014).

    Article  PubMed  CAS  Google Scholar 

  7. Theander, E. et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann. Rheum. Dis. 73, 407–413 (2014).

    Article  PubMed  Google Scholar 

  8. Mease, P. J. et al. Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. RMD Open 4, e000638 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

Download references


H.A.-M. is funded as a National Institute for Health Research clinical lecturer and Oxford-UCB prize fellow. L.C.C is funded by a National Institute for Health Research Clinician Scientist award. The work of the authors is supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed in this commentary are those of the authors and not necessarily those of the NHS, the NIHR or the UK Department of Health.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Laura C. Coates.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Al-Mossawi, H., Coates, L.C. Personalized medicine — a new reality in psoriatic arthritis?. Nat Rev Rheumatol 14, 449–451 (2018).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing